Novel cytomegalovirus UL54 DNA Polymerase gene mutations selected in vitro that confer brincidofovir resistance

Sunwen Chou, Ronald J. Ercolani, E. Randall Lanier

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Eight in vitro selection experiments under brincidofovir pressure elicited the known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L and the novel exonuclease domain substitutions D413Y, E303D, and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir or 17-fold when E303G was combined with V812L. The new exonuclease domain I resistance mutations selected under brincidofovir pressure add to the single instance previously reported and show the expected patterns of cross-resistance.

Original languageEnglish (US)
Pages (from-to)3845-3848
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume60
Issue number6
DOIs
StatePublished - Jun 2016

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Novel cytomegalovirus UL54 DNA Polymerase gene mutations selected in vitro that confer brincidofovir resistance'. Together they form a unique fingerprint.

Cite this